A syndrome he does not have yet

Review and sources

Not clinically reviewed. No clinician has signed this scenario.

• Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993;94(2):133-139. 102 patients receiving combination chemotherapy. "Laboratory tumor lysis" defined as two of a 25% rise in serum phosphate, potassium, uric acid or urea nitrogen, or a 25% fall in calcium, within 4 days of treatment. "Clinical tumor lysis" defined as laboratory tumor lysis plus one of potassium above 6 mmol/L, creatinine above 221 micromol/L, calcium below 1.5 mmol/L, a life-threatening arrhythmia, or sudden death. Laboratory tumor lysis occurred in 42% and clinical in 6%; clinical tumor lysis occurred more frequently in patients with pretreatment renal insufficiency.
• Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries. Leuk Lymphoma. 2003;44(1):77-83. 788 patients screened retrospectively in Belgium, the Netherlands, Spain and the UK. Hyperuricaemia occurred in 18.9% of patients, and 27.8% of those fulfilled tumour-lysis criteria. The authors note the observed incidence rates were lower than earlier reports.
• Duminuco A, Del Fabro V, De Luca P, Leotta D. Emergencies in Hematology: Why, When and How I Treat? J Clin Med. 2024;13(24):7572. A narrative review. Laboratory data may be present in the first 6 to 24 hours after chemotherapy starts, and the first clinical signs appear in the first 48 to 72 hours. This review restates Annemans et al. as a laboratory tumour-lysis incidence of 18.9% with clinical at 5%, which is not what that study reported.